department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Candel Therapeutics, Inc. ($CADL) · pharmadog

PUBLIC COMPANY

$CADLCandel Therapeutics, Inc.

Needham, MA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 11Phase 3

aglatimagene besadenovec

Prostate Cancer

High-Grade Glioma

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Candel Therapeutics, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$CADL

SEC CIK

0001841387

country

US

source

sec_tickers

top tags

Oncology2 NSCLC1 Prostate Cancer1

mentioned in

0news items

entity-linker matched

Data sources

last refreshed 28m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$CADL

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovecrecruitingn=45
phase2CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCactive not recruitingn=90
phase3Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Canceractive not recruitingn=711
phase2Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)active not recruitingn=187
phase1Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancercompletedn=12
phase1GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomascompletedn=41
phase2Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Gliomacompletedn=52
phase2Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinomaactive not recruitingn=54

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 23, 26BUYManning Paul B· director550,458 sh @ $5.45$3.00M↗

routine RSU / option mechanics (6)

Mar 31, 26grantManning Paul B · director4,618 sh
Mar 31, 26grantPAPA JOSEPH C · director2,795 sh
Mar 31, 26grantLoggia Nicoletta · director779 sh
Jan 26, 26grantTak Paul Peter · Chief Executive Officer629,000 sh
Jan 26, 26grantBarone Francesca · Chief Scientific Officer232,000 sh
Jan 26, 26grantTyagarajan Seshu · Chief Technology Officer154,000 sh